Show simple item record

dc.contributor.authorLevy, Jonathan I.en_US
dc.contributor.authorBuonocore, Jonathan J.en_US
dc.contributor.authorvon Stackelberg, Katherineen_US
dc.date.accessioned2011-12-29T22:49:47Z
dc.date.available2011-12-29T22:49:47Z
dc.date.copyright2010
dc.date.issued2010-10-27
dc.identifier.citationLevy, Jonathan I, Jonathan J Buonocore, Katherine von Stackelberg. "Evaluation of the public health impacts of traffic congestion: a health risk assessment" Environmental Health 9:65. (2010)
dc.identifier.issn1476-069X
dc.identifier.urihttp://hdl.handle.net/2144/2618
dc.description.abstractBACKGROUND: Traffic congestion is a significant issue in urban areas in the United States and around the world. Previous analyses have estimated the economic costs of congestion, related to fuel and time wasted, but few have quantified the public health impacts or determined how these impacts compare in magnitude to the economic costs. Moreover, the relative magnitudes of economic and public health impacts of congestion would be expected to vary significantly across urban areas, as a function of road infrastructure, population density, and atmospheric conditions influencing pollutant formation, but this variability has not been explored. METHODS: In this study, we evaluate the public health impacts of ambient exposures to fine particulate matter (PM2.5) concentrations associated with a business-as-usual scenario of predicted traffic congestion. We evaluate 83 individual urban areas using traffic demand models to estimate the degree of congestion in each area from 2000 to 2030. We link traffic volume and speed data with the MOBILE6 model to characterize emissions of PM2.5 and particle precursors attributable to congestion, and we use a source-receptor matrix to evaluate the impact of these emissions on ambient PM2.5 concentrations. Marginal concentration changes are related to a concentration-response function for mortality, with a value of statistical life approach used to monetize the impacts. RESULTS: We estimate that the monetized value of PM2.5-related mortality attributable to congestion in these 83 cities in 2000 was approximately $31 billion (2007 dollars), as compared with a value of time and fuel wasted of $60 billion. In future years, the economic impacts grow (to over $100 billion in 2030) while the public health impacts decrease to $13 billion in 2020 before increasing to $17 billion in 2030, given increasing population and congestion but lower emissions per vehicle. Across cities and years, the public health impacts range from more than an order of magnitude less to in excess of the economic impacts. CONCLUSIONS: Our analyses indicate that the public health impacts of congestion may be significant enough in magnitude, at least in some urban areas, to be considered in future evaluations of the benefits of policies to mitigate congestion.en_US
dc.description.sponsorshipAmerican Road and Transportation Builders Associationen_US
dc.language.isoenen_US
dc.publisherBioMed Centralen_US
dc.rightsCopyright 2010 Levy et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/2.0
dc.titleEvaluation of the Public Health Impacts of Traffic Congestion: A Health Risk Assessmenten_US
dc.typearticleen_US
dc.identifier.doi10.1186/1476-069X-9-65
dc.identifier.pubmedid20979626
dc.identifier.pmcid2987789


Files in this item

This item appears in the following Collection(s)

Show simple item record

Copyright 2010 Levy et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as Copyright 2010 Levy et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.